Breast & ovarian cancer inheritance risk explained

General Population

~12% of women in the general population will develop breast cancer sometime during their lives.

BRCA1 gene defect

55-65% of women who inherit a harmful BRCA1 mutation will develop breast cancer by age 70 years.

BRCA2 gene defect

45% of women who inherit a harmful BRCA2 mutation will develop breast cancer by age 70 years.

Research has shown that India has a three times higher incidence rate of hereditary breast and ovarian cancer compared to the West.

* Studies conducted by Strand Life Sciences

How can I find out if my cancer diagnosis or an affected family member's cancer is hereditary?

  • The initial step in addressing this question would be to talk to a genetic counsellor (healthcare professionals with training in medical genetics and counselling).
  • A genetic counsellor can help you understand if the cancer in your family is hereditary, and start the genetic testing process in a timely manner.

Who should be considered for genetic testing?

  1. Patients diagnosed with breast or ovarian cancer, and fulfilling any one of the following criterla:
    • Family history of breast or ovarian cancer or pancreatic cancer (family history means - cancer in siblings, cousins, parents' siblings and cousins, as well as in grandparents).
    • Early onset breast cancer (<45 years).
    • Bilateral breast cancer.
    • Triple negative breast cancer (<60 years).
    • Male breast cancer at any age.
    • Ovarian cancer at any age.
  2. Unaffected individuals with a family history of cancer.

What are the benefits of doing this test?

The test provides the following benefits:

  • Patients with cancer can determine if their cancer is hereditary in nature, therefore putting them at increased risk of secondary cancers later in life.
  • The test provides useful information for making treatment or surgical decisions.
  • Risk-estimation (prediction of cancer risk) in unaffected family members.
  • Based on the test results, high risk members in a family can be put on targeted early surveillance measures and life-style changes to prevent cancer.

Watch and read about patients who have benefited from genetic testing

A case of recurring Ovarian

Battling an aggressive

We impact lives through the power of precision medicine. Thousands of patients have put their trust in us.

Read more stories...

Know your hereditary
cancer risk

Use our risk calculator to estimate your hereditary cancer risk

Take the Strand Hereditary Cancer Risk Test

Talk to our genetic counsellors

We are here to help!

Contact us

What sample is required to perform this test?

The Strand® Hereditary Breast and Ovarian Cancer test can be performed using any one of these samples:

  • Saliva (collection kits will be provided with instructions)
  • Buccal swab (collection kits will be provided with instructions)
  • Blood sample

Step-by-step procedure for saliva sample collection

Who can prescribe this test?

Your oncologist or physician can prescribe the Strand® Hereditary Breast and Ovarian Cancer Test.

How long will it take for the test results to be available?

The test results will be made available to your physician within 3-4 weeks of submitting the sample.

Genetic Testing for Hereditary Cancer – Frequently Asked Questions

About Strand

A History of Innovative Genomic Research

Strand Life Sciences is a global genomic profling company and leader in precision medicine diagnostics, aimed at empowering cancer care and genetic testing for inherited diseases. Strand works with physicians and hospitals to enable faster clinical decision support for accurate molecular diagnosis, prognosis, therapy recommendations, and clinical trials. Strand Life Sciences is a CAP & NABL accredited NGS laboratory.